The global Fuchs Endothelial Corneal Dystrophy (FECD) Market garnered a market value of USD 180 Billion in 2023 and is expected to accumulate a market value of USD 370 Billion by registering a CAGR of 7.5% in the forecast period 2023 to 2033.
The expanding worldwide aging population, as well as increased awareness of eye illnesses and corneal donation, is likely to boost the market. Furthermore, increased research interest in cellular treatment techniques is expected to generate significant potential for the Industry in the coming years.
The increased incidence of diabetes throughout the world will be a primary driver, resulting in an increase in the market's growth rate. According to the American Optometric Association, approximately 7 million people in the United States have undiagnosed diabetes, with 12,000 to 24,000 people losing their sight each year.
Diabetic retinopathy is the leading cause of blindness in the United States today. Diabetic individuals must get a dilated eye exam once a year. By keeping a watch out for retinal anomalies, diabetic issues such as blindness and other consequences can be prevented.
In addition, the occurrence of different diseases such as cataracts, glaucoma, and age-related macular degeneration will drive market expansion.
The growing healthcare spending, which aids in the improvement of its infrastructure, is a crucial element driving the growth rate of the market. Furthermore, numerous government organizations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 180 Billion |
| Anticipated Forecast Value (2033) | USD 370 Billion |
| Projected Growth Rate (2023 to 2033) | 7.5% CAGR |
The global demand for Fuchs Endothelial Corneal Dystrophy (FECD) is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of USD 370 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6%.
The growing elderly population is expected to boost the market's growth rate. According to the World Ageing 2020 projection, there will be 727 million individuals aged 65 and over in 2020.
This population is predicted to reach 1.5 billion by 2050. The proportion of the population aged 65 and older is expected to climb from 9.3% in 2020 to around 16.0% in 2050. The geriatric population is predicted to expand, and this group will require housing.
Furthermore, the growing number of government activities to raise awareness and change people's sedentary lifestyles will result in the rise of the market. Along with this, increased disposable income and expanding government-friendly programs would boost the market’s growth.
The market's expansion is being propelled by an increase in the number of Research and Development activities. This would create advantageous prospects for the expansion of the market.
Novel entrants are concentrating their efforts on developing new steroid-based formulations to treat dry eye syndrome (DES), which is also a key driving factor in the market.
Expanding Worldwide Ageing Population to Improve Maintenance and Performance
The expanding worldwide ageing population, as well as increased awareness of eye illnesses and corneal donation, are likely to boost the market. Population growth and ageing are likely to drive up demand for eye care in the coming years.
With the world's ageing population, the demand for corneal transplantation is expected to climb dramatically throughout the anticipated period.
Furthermore, researchers throughout the world are studying and developing novel technologies to guarantee the prompt treatment of individuals with Fuchs endothelial corneal dystrophy (FECD). Rising cellular therapy research activity is expected to generate significant prospects for the global market in the coming years.
Dangers Associated with Surgical Intervention to Slow Down the Market Growth
The dangers associated with surgical intervention, as well as a scarcity of donor grafts, may have an impact on market growth.
Progressive Acceptance of Upgraded Technology to Widen Profit Margins
Asian nations are predicted to develop the quickest due to rising awareness, enhanced personal care and cleanliness, increased diagnostic rates, progressive acceptance of upgraded technology, rising disposable income, and burgeoning healthcare infrastructures. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.
Greater Healthcare Knowledge to Accelerate the Market
Because of greater healthcare knowledge, illness incidence, and a high rate of diagnosis, North America was found to have the highest share of the market.
In this multi-screen universe, individuals of all ages may be found. Computer or digital screen usage may result in less blinking, which may add to symptoms of Fuchs Endothelial Corneal Dystrophy (FECD), hence boosting the need for better and more effective Fuchs Endothelial Corneal Dystrophy (FECD) therapies, which is projected to stimulate growth in the North American region analyzed.
Furthermore, the region's expanding elderly population is driving market expansion since they are more susceptible to numerous ocular ailments such as Fuchs Endothelial Corneal Dystrophy (FECD). North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.
Increased Research and Development to Drive the Market Growth
With increased research and development, Europe is providing the second-highest share of the Fuchs endothelial corneal dystrophy (FECD) market.
Europe is the leading market for corneal transplants, and it will continue to grow in the near future due to the availability of various treatment options and prevention strategies, as well as the growing influence of organ donation programs and growing government focus on organ donation policies.
Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.
The Hospitals Segment to enhance Sales Prospects
The Fuchs Endothelial Corneal Dystrophy (FECD) market is divided into three segments based on end-users: hospitals, ASCS, and others. The hospital's segment accounts for the majority of the worldwide market.
Key start-up players in the Fuchs Endothelial Corneal Dystrophy (FECD) are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Fuchs Endothelial Corneal Dystrophy (FECD) start-ups are as follows:
The market for Fuchs Endothelial Corneal Dystrophy (FECD) is moderately competitive. With regard to market share, the industry is currently dominated by a few significant competitors. With the growing senior population and high illness incidence, a few new smaller competitors are projected to enter the industry in the next years.
Key players in the Fuchs endothelial corneal dystrophy market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc, and Presbia Plc.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 180 Billion |
| Market Value in 2033 | USD 370 Billion |
| Growth Rate | CAGR of 7.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, Diagnosis, End Users, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Middle East and Africa (MEA) |
| Key Countries Profiled | The US, Canada, Brazil, Mexico, BENELUX, France, Germany, Italy, Nordics, Spain, The UK, Poland, Russia, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Kowa Pharmaceuticals; Trefoil Therapeutics; Alcon; Emmecell; Santen; AJL Ophthalmic SA; Massachusetts Eye and Ear; KeraMed, Inc.; Presbia Plc |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: APAC Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 23: APAC Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 24: APAC Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 18: Global Market Attractiveness by Diagnosis, 2023 to 2033
Figure 19: Global Market Attractiveness by End Users, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End Users, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 38: North America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 39: North America Market Attractiveness by End Users, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End Users, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End Users, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by End Users, 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by End Users, 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by End Users, 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by End Users, 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: APAC Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 102: APAC Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 103: APAC Market Value (US$ Million) by End Users, 2023 to 2033
Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: APAC Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 109: APAC Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 110: APAC Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 111: APAC Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 112: APAC Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 113: APAC Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 114: APAC Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 115: APAC Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 116: APAC Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 117: APAC Market Attractiveness by Treatment, 2023 to 2033
Figure 118: APAC Market Attractiveness by Diagnosis, 2023 to 2033
Figure 119: APAC Market Attractiveness by End Users, 2023 to 2033
Figure 120: APAC Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by End Users, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 137: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 138: MEA Market Attractiveness by Diagnosis, 2023 to 2033
Figure 139: MEA Market Attractiveness by End Users, 2023 to 2033
Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of USD 180 Billion
The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of USD 370 Billion
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.
Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc and Presbia Plc.
North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.
The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) in the forecast period 2023-2033.
Fuchs Endothelial Corneal Dystrophy (FECD) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
